Project Grant K99CA293266
Award Date 9/12/25
Completion Date 8/31/26
Dollars Obligated $156K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $527,159 in funding to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to conduct research on the role of DNA damage and cell fate plasticity in the initiation of BRCA1-related basal-like breast cancer. The key objectives of the research are to: 1) study whether BRCA1-deficient luminal mammary cells acquire a fetal mammary stem cell-like gene expression program...
- This $470,567.00 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) aims to identify molecular features that contribute to response or resistance to PARP-inhibitor therapy in metastatic breast cancer patients without germline BRCA1/2 mutations. The key activities under this 2-year research project involve analyzing pre-treatment tumor DNA and pre- and post-treatment circulating tumor DNA in...
- This $156,000 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support a 5-year national multi-institutional retrospective cohort study examining breast cancer diagnostics, treatments, and outcomes in individuals on hormone therapy. The Medical College of Wisconsin, Inc. is the prime awardee and will create the national cohort, analyze data on breast cancer stage, treatment, and survival, and establish a patient and community...
- This $744,575 project grant was awarded on May 16, 2025 by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. The grant is funding research at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to define the genomic and biologic impact of LINE-1 activity in fallopian tube epithelial cells and its role in the development of high-grade serous ovarian cancer (HGSOC). The research involves...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $101,916.00 to the University of Massachusetts Medical School to investigate factors contributing to chemoresistance in BRCA mutant hereditary breast and ovarian cancers. The overall goal is to gain a new understanding of the mechanisms behind chemoresistance in these cancers, which frequently develop resistance to existing chemotherapies and PARP inhibitors. The research aims to...
- This federal Project Grant award of $412,429.00, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research at the Mayo Clinic to investigate novel approaches for treating high-grade serous ovarian cancer (HGSOC). The research aims to evaluate how the nuclear translocation of cathepsin L (NCTSL) can sensitize CCNE1-driven HGSOC tumors to combination therapies involving DNA-damaging agents and PARP inhibitors. Key objectives include...
- This federal Project Grant award of $165,883 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports a research project led by Dr. Xinyuan (Cindy) Zhang at Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to improve early detection, causal inference, and lifestyle-based prevention for hepatocellular carcinoma (HCC). The key objectives of this 2-year research project are to: Use computational biology and system biology techniques to...
- This $137,322 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research by Trustees of Boston University to develop disulfated polyamidosaccharide nanoparticles as a P-selectin targeting chemotherapeutic delivery system. The goal is to create a more targeted and effective treatment for breast and lung cancers, which disproportionately affect women, including many non-smokers. The research will leverage the upregulation of P-selectin on...
- This National Institutes of Health National Cancer Institute Project Grant of $470,532 provides funding from July 1, 2022 to June 30, 2027 to Brigham and Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, to characterize immunometabolic pathways enabled by PARP inhibition in breast cancer. The grant aims to (1) define the mechanisms by which PARP inhibitors induce lipogenic tumor-associated macrophage development, (2) determine how lipogenic macrophages suppress...
- The Project Grant award titled "The Genetic Epidemiology of Radiation-Associated Contralateral Breast Cancer" was provided by the National Cancer Institute (NCI) under the federal Cancer Cause and Prevention Research grant program (CFDA 93.393). The $1,504,098 award to the Sloan-Kettering Institute for Cancer Research aims to identify the genetic determinants of radiation-associated breast cancer and develop detailed risk estimation models for contralateral breast cancer. The project...